[Change of antimalarial first-line treatment in Burkina Faso in 2005]. / Les raisons d'un changement de médicaments de première intention pour le traitement du paludisme simple au Burkina Faso en 2005.
Bull Soc Pathol Exot
; 102(1): 31-5, 2009 Feb.
Article
em Fr
| MEDLINE
| ID: mdl-19343918
ABSTRACT
Burkina Faso has recently changed the antimalarial drug policy to artesunate/amodiaquine or artemether/lumefantrine as the first-line antimalarial drug and sulfadoxine/pyrimethamine for the intermittent preventive treatment in pregnant woman. Before the implementation of this new strategy we conducted an in vivo efficacy study with chloroquine or sulfadoxine/pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in urban area of Burkina from September to December 2003. Chloroquine (25 mg/kg over 3 days) or sulfadoxine/pyrimethamine (25 mg/kg + 0.025 mg/kg single dose) was administered respectively to 137 and 125 children aged from 6 to 59 months old in a randomized, opened study. Follow up extended over 28 days using modified WHO protocol. After adjusting the results by PCR, treatment failures rates were 63.4% (83/131) and 13.8% (17/123) respectively for chloroquine and sulfadoxine/pyrimethamine. These results with other observations have justified the change of malaria therapy policy in Burkina Faso in 2005.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antimaláricos
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Animals
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Pregnancy
País/Região como assunto:
Africa
Idioma:
Fr
Revista:
Bull Soc Pathol Exot
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Burquina Fasso